Safety outcomes of Alteplase among acute ischemic stroke patients with special characteristics

Neurocritical Care

Volumn 6, Issue 3, 2007, Pages 181-185

  Sylaja, P N ^a   Dong, Wei ^b   Grotta, James C ^c   Miller, Mary K ^b   Tomita, Kristen ^b   Hamilton, Scott ^d   Semba, Charles ^b   Hill, Michael D ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b GENENTECH INC   (United States)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^d STANFORD UNIVERSITY   (United States)

Author keywords

Acute ischemic stroke; Thrombolysis; Tissue plasminogen activator

Indexed keywords

ALTEPLASE; FIBRINOLYTIC AGENT; TISSUE PLASMINOGEN ACTIVATOR;

ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL FEATURE; CONTROLLED STUDY; DRUG SAFETY; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT OUTCOME; AGED; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONVALESCENCE; DIABETES MELLITUS; HISPANIC; HOSPITALIZATION; META ANALYSIS; PATHOPHYSIOLOGY; PROSPECTIVE STUDY;

AGED; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; CEREBROVASCULAR ACCIDENT; DIABETES COMPLICATIONS; FIBRINOLYTIC AGENTS; HEART FAILURE, CONGESTIVE; HISPANIC AMERICANS; HUMANS; PROSPECTIVE STUDIES; RECOVERY OF FUNCTION; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TISSUE PLASMINOGEN ACTIVATOR;

EID: 34948857543     PISSN: 15416933     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12028-007-0018-8     Document Type: Article

References (19)

1. Graham GD. Tissue plasminogen activator for acute ischemic stroke in clinical practice. A meta-analysis of safety data. Stroke 2003;34:2847-50.
2. NINDS rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-7.
3. Larrue V, von Kummer R, del Zoppo G, Bluhmki T. Hemorrhagic transformation in acute ischemic stroke: potential contributing factors in the European Cooperative Acute Stroke Study. Stroke 1997;28:957-60.
4. The NINDS t-PA Stroke Study Group. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. Stroke 1997;28:2109-18.
5. Larrue V, von Kummer R, Muller A, Bluhmki E. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study. Stroke 2001;32:438-41.
6. Hill MD, Buchan AM, for the Canadian Alteplase for Stroke Effectiveness Study (CASES) Investigators. Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study. CMAJ 2005;172:1307-12.
7. Okada Y, Yamaguchi T, Minematsu K, Miyashita T, Sawada T, Sadoshima S et al. Hemorrhagic transformation in cerebral embolic stroke. Stroke 1989;20:589-603.
8. Tanne D, Kasner SE, Demchuk AM, Koren-Morag N, Hanson S, Grond M et al. Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator for acute ischemic stroke in clinical practice: the Multicenter rt-PA Acute Stroke Survey. Circulation 2002;105:1679-85.
9. Gurwitz JH, Gore JM, Gold berg RJ, Barron HV, Breen T, Rundle AC et al. Risk for intracranial hemorrhage after tissue plasminogen activator treatment for acute myocardial infarction: participants in the national registry of myocardial infarction 2. Ann Intern Med 1998;129:597-604.
10. Tanne D, Gorman MJ, Bates VE, Kasner SE, Scott P, Verro P et al. The tPA Stroke Survey Group. Intravenous tissue plasminogen activator for acute ischemic stroke in patients aged 80 years and older. The tPA Stroke Survey experience. Stroke 2000;31:370-5.
11. Berrouschot J, Röther J, Glahn J, Kucinski T, Fiehler J, Thomalla G. Outcome and severe hemorrhagic complications of intravenous thrombolysis with tissue plasminogen activator in very old (≥80 years) stroke patients. Stroke 2005;36:2421-5.
12. Sylaja PN, Cote R, Buchan AM, Hill MD. Thrombolysis for acute ischemic stroke patients aged 80 years and older: Canadian Alteplase for stroke effectiveness study. J Neurol Neurosurg Psychiatry 2006;77:826-29.
13. Heuschmann PU, Kolominsky-Rabas PL, Roether J, Misselwitz B, Lowitzsch K, Heidrich J et al. Predictors of in-hospital mortality in patients with acute ischemic stroke treated with thrombolytic therapy. JAMA 2004;292:1831-1838.
14. Demchuk AM, Morgenstern LB, Krieger DW, Linda Chi T, Hu W, Wein TH et al. Serum glucose level and diabetes predict tissue plasminogen activator-related intracerebral hemorrhage in acute ischemic stroke. Stroke 1999;30:34-39.
15. Kase CS, Furlan AJ, Wechsler LR, Higashida RT, Rowley HA, Hart RG et al. and PROACT II investigators. Cerebral hemorrhage after intra-arterial thrombolysis for ischemic stroke. the PROACT II trial. Neurology 2001;57:1603-10.
16. Katzan IL, Furlan AJ, Lloyd LE, Frank JI, Harper DL, Hinchey JA et al. Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience. JAMA 2000;283:1151-8.
17. Stansbury JP, Huanguang J, Williams LS, Vogel WB, Duncan PW. Ethnic disparities in stroke: epidemiology,acute care and postacute outcomes. Stroke 2005;36:374-87.
18. Frey JL, Jahnke HK, Bulfinch EW. Differences in stroke between white, Hispanic, and Native American patients. the Barrow Neurological Institute stroke database. Stroke 1998;29:29-33.
19. Trouillas P, Nighoghossian N, Derex L, Adeleine P, Honnorat J, Neuschwander P et al. Thrombolysis with intravenous rtPA in a series of 100 cases of acute carotid territory stroke: determination of etiological, topographic,and radiological outcome factors. Stroke 1998;29:2529-40.